drugset / Trial / NCT01173471

A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure

NCT01173471

Phase 2 Completed 50 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to evaluate the efficacy of systemically administered AZD4017, compared with placebo, over a 28-day period in patients with raised intra-ocular pressure (IOP).

Timeline

Start
2010-12
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD4017 Small molecule 200 mg Oral
Subject AZD4017 Small molecule 800 mg Oral

Indications